CMS

867
9.9101.69% ( -0.170 )
Delay Closed: Nov 16, 16:08:11

Overview

CMS (867)

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republi...

Open
10.230
High
10.380
Low
9.815
Prev. Close
10.080
Volume
5.14M
Turnover
50.86M
Avg Price
9.905
Bid/Ask Ratio
-71.43%
Amplitude
5.61%
52wk High
15.088
Volume Ratio
0.78
Turnover Ratio
0.21%
52wk Low
9.354
HK Mkt Cap
24.11B
Market CapHKD
24.11B
P/ETTM
13.65
P/EDynamic
10.62
P/EStatic
--
EPSTTM
0.726
EPSDynamic
0.933
EPSStatic
--
BVPS
8.49
P/B
1.17
HK Shares
2.43B
Dividend YieldTTM
3.48%
DividendTTM
0.344
Shares
2.43B
Min lot size
1,000
Currency
HKD

CMS Analyst Rating

View more

Forecast & Rating

Sep 28, 2026
Price forecast
HK$17.6477.99%
Forecast & RatingStrong buy
10analysts
  • Strong buy80.00%
  • Buy10.00%
  • Hold10.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    China Medical System shares slipped to HKD 9.910 today, down roughly 1.69% from yesterday's close of HKD 10.080. Recent regulatory approvals in Singapore and China for Ruxolitinib Phosphate Cream treating vitiligo and atopic dermatitis expanded the company's product pipeline, though market reception remained muted. Fundamentals appear stable with Q1-Q2 revenues growing 19.27% and 18.55% year-over-year respectively, net profit growth of 10-11% YoY, and EPS advancing to HKD 0.2354 while holding a steady net margin of 21.91%. However, significant headwinds persist: the stock has tumbled 24.41% year-to-date from HKD 13.11, down over 36% from its 52-week high of HKD 15.52, now trading well below both its 20-day moving average of HKD 10.152 and 60-day moving average of HKD 10.634. Current valuations at PE 13.65x and PB 1.17x appear relatively inexpensive, likely reflecting ongoing repricing of prior elevated expectations.

  2. Nov, 13

    China Medical System (867.HK) declined 2.42% today, primarily reflecting profit-taking pressure after recent momentum. The company delivered multiple product breakthroughs: ruxolitinib phosphate cream secured Singapore approval for vitiligo treatment, while Silevimig injection—the world's first bispecific antibody against rabies—initiated prescriptions domestically. Q2 fundamentals remained robust with revenue of HKD 2.599 billion (up 18.55% YoY), operating income rising 25.47%, EPS of HKD 0.2354 (up 10.39% YoY), and net profit margin sustained at 21.9%. Goldman Sachs maintains Buy rating with target price of HKD 17.96. Year-to-date, the stock has fallen 23.11% and trades below both MA20 (10.167) and MA60 (10.666), remaining 35% below its 52-week high of HKD 15.52. While valuation appears reasonable at PE 13.89 and PB 1.19, near-term momentum will depend on sustained earnings growth and pipeline progression.

  3. Nov, 12

    Kangzhe Pharmaceuticals closed marginally lower at HKD 10.33, down 0.6%, likely following profit-taking after the recent 5% rally on November 9. The company's Q2 2026 fundamentals remain robust: revenue reached HKD 2.599 billion with 18.55% year-over-year growth, operating profit surged 25.47% YoY to HKD 573 million, and EPS expanded 10.39% to HKD 0.2354. The product pipeline continues advancing: ruxolitinib phosphate cream gained Singapore approval for vitiligo treatment, Lumirix secured a new indication in China for atopic dermatitis, and Silevimig—the world's first bispecific antibody against rabies—achieved initial prescriptions in China. Goldman Sachs maintained its 'Buy' rating with a target price cut to HKD 17.96. The stock has retreated 33.44% from its 52-week high of HKD 15.52 to near the recent low of HKD 9.49, reflecting a year-to-date decline of 21.21% as prior premium valuations have been significantly digested.

  4. Nov, 11

    China Medical System (867.HK) slipped 1.42% to HKD10.39, retreating from intraday high HKD10.49 after an initial morning bounce, as investors banked gains following recent regulatory wins—ruxolitinib phosphate cream approval in Singapore and Lumirix new indication approval in China—that had buoyed sentiment. Fundamentals retain cushion: Q2 revenue of HKD2.599 billion (up 18.55% YoY) and net profit of HKD569.5 million (up 10.44% YoY) both grew, sustaining a 21.91% margin. Yet the equity has ceded 20.75% year-to-date from HKD13.11 and trades 33% below its 52-week high of HKD15.52 (Feb 24). On valuation, Goldman Sachs trimmed its price target to HKD17.96 but kept a Buy rating, suggesting limited downside; the current PE of 14.32 and PB of 1.22 do not imply overextension, though the stock's technical position between MA20 (HKD10.19) and MA60 (HKD10.72) points to near-term consolidation.

  5. Nov, 10

    Kangzhe Pharma fell 1.13% to HKD 10.54, mainly profit-taking after the prior rally. Morning highs of HKD 10.76 (09:35) faded to afternoon lows of HKD 10.49 (15:54). Q2 earnings stayed solid—revenue of HKD 2.599 billion (up 18.55% YoY), net profit of HKD 569 million (up 10.44%), with a 21.91% net margin. Recent regulatory approvals for dermatology products in Singapore and domestic label expansions provide support. Goldman Sachs cut its target to HKD 17.96 but kept Buy rating, signaling the market is pricing in slower revenue growth. The stock is off 19.6% year-to-date and near 52-week lows of HKD 9.49; P/E of 14.5x remains reasonable.

News